Biotechnology, cannabis medicine, and the rapid advancements in artificial intelligence (AI) and machine learning (ML) are beginning to converge.

Hemant Kumar Bid, program director for the Master of Science in Biotechnology and the Medical Cannabis concentration at Morehouse School of Medicine, believes this convergence could dramatically accelerate the development of cannabis-based therapies. With AI, cannabis medicine may move beyond today’s trial-and-error approach toward more personalized, precise treatments.

Biotechnology combines biological science with advanced technology to develop medical solutions, including drug discovery, genetic engineering, and diagnostic tools. “Modern biotechnology focuses on molecular biology, genetic engineering, and advanced cell culture techniques. This is where it will advance cannabis medicine,” explains Bid.

The Foundational Elements of AI and Machine Learning

AI and machine learning are closely related but serve distinct roles.

AI refers to computer systems designed to perform tasks that usually require human intelligence, such as reasoning, pattern recognition, and decision-making. Machine learning, a branch of AI, identifies patterns in large datasets, improves as it processes more data, and predicts future outcomes.

Many AI systems rely on deep learning, a method using neural networks to detect complex patterns across massive datasets. Another important capability is natural language processing (NLP), which allows computers to understand and generate human language and analyze vast bodies of scientific literature, uncovering insights and connections that might otherwise take researchers years to identify.

Machine learning is already widely used in biotechnology to analyze complex biological data and predict how molecules behave in the body.

AI in Drug Discovery and Development

AI is rapidly transforming how new drugs are discovered and developed.

Traditionally, drug discovery depends heavily on animal models and laboratory testing—a slow, expensive trial-and-error process. Machine learning can now analyze large molecular datasets to predict which cannabinoid compounds interact with specific receptors, such as CB1, CB2, TRPV1, GPR55, and serotonin receptors. This capability can significantly reduce both the time and cost of traditional drug discovery.

AI can also predict toxicity and safety risks in drug formulations before human testing begins. “Once a clinician knows that toxicity will exceed 70%, they can decide not to move forward,” says Bid.

In addition, NLP tools can mine extensive cannabis research literature to identify emerging therapeutic targets and gaps in current studies.

Personalized Cannabis Medicine

Many diseases are complex, and scientists are still uncovering their underlying causes. Conditions such as cancer may be influenced by a combination of genetics, lifestyle, and environmental factors.

Deep learning systems can analyze pathology images and genetic data at a level beyond human capability. They can detect subtle changes in DNA, RNA, or protein structures that influence disease progression and treatment outcomes. These insights are opening the door to how personalized approaches can be applied to cannabis medicine.

Machine learning models are already being applied to pharmacogenomic data to predict how a patient will metabolize cannabinoids based on genetic variation, particularly in liver-metabolizing enzymes like cytochrome P450, which play a key role in metabolizing THC and CBD.

“That means this genomics and pharmacogenomics approach, using machine learning models, could help predict efficacy and adverse effects before treatment begins,” says Bid.

AI and ML systems can also analyze genetic mutations, disease risk, and patient data to suggest individualized treatment plans. Factors such as genetics, medical history, symptoms, prior cannabis use, disease severity, and previous treatment responses can all inform personalized decisions. Because everyone’s DNA and endocannabinoid system differ, a one-size-fits-all approach to cannabis medicine is ineffective.

Identifying Endocannabinoid Dysfunction

Bid emphasizes that more genetic research is needed to understand how the endocannabinoid system varies across populations worldwide. Without sufficient patient data, it is difficult to identify patterns of endocannabinoid dysfunction or determine which cannabis treatments are most effective.

Mobile applications like Strainprint are already tracking cannabis use and therapeutic outcomes, collecting valuable real-world patient data. These platforms can generate large datasets on dosing, product type, symptoms, and treatment results. AI can use this data to predict treatment response and support personalized medicine.

Such datasets may also help researchers identify patterns of endocannabinoid dysfunction and develop needed standardized diagnostic tools.

Today, many cannabis physicians still rely on trial and error when determining dosing and treatment protocols. AI-driven analysis of large patient datasets could dramatically accelerate the development of evidence-based guidelines.

Connecting Microbiome Insights

Emerging research increasingly links the gut microbiome to a wide range of diseases. AI-driven microbiome analysis, paired with endocannabinoid profiling, can identify biomarkers of gut health and guide interventions—from dietary modifications and probiotics to customized cannabinoid formulations.

Since most cannabinoid receptors reside in the gut, endocannabinoid deficiencies often intersect with microbiome imbalances. This integration highlights the importance of combining microbiome and endocannabinoid insights for effective treatment.

AI for Cannabis Safety and Patient Monitoring

AI applications in electronic health records and patient-reported databases can accelerate the detection of adverse effects associated with cannabis use. Traditional pharmacovigilance methods can take months or years to identify safety signals, but AI-driven analytics can flag potential risks in near real-time. This allows healthcare providers to optimize treatment plans, mitigate harm, and make data-driven decisions.

Transforming Clinical Trials

Clinical trials are the gold standard for evaluating new medicines and are required for FDA approval. Yet they remain costly, time-consuming, and often slow the development of innovative therapies.

AI can identify patients most likely to respond to specific treatments, improving trial success rates while reducing costs and timelines. By accelerating clinical trials, AI could speed the development of standardized cannabis medicines, strengthen regulatory oversight, and bring safe, effective therapies to patients faster.

AI and Cannabis Plant Science

Advances in plant science are shaping the future of cannabis medicine. Researchers now understand much of the cannabis genome and the biosynthetic pathways that produce cannabinoids, terpenes, alkaloids, and flavonoids. Breeders and cultivators have the ability to manipulate these pathways to achieve precise therapeutic outcomes.

New cannabinoids are being discovered faster than physicians can test and integrate them into treatment plans. Because cannabis plants are highly variable in their chemistry, AI could bring precision and consistency to breeding and cultivation. Machine learning models trained on spectroscopic data can predict cannabinoid and terpene content without the need for extensive lab testing.

“Since the plant is highly variable in its chemistry, we need AI to ensure precision and consistency in breeding and cultivation,” says Bid.

The Need for Data and Expertise

Despite the need for AI-driven cannabis medicine, large-scale datasets required to train effective machine learning models remain limited. And relatively few physicians have formal training in cannabis medicine.

Meanwhile, the pace of cannabinoid discovery in plant science continues to accelerate, widening the gap between scientific knowledge and clinical practice.

Potential Risks and Ethical Considerations

While AI offers enormous potential, it also raises important ethical and practical concerns. Large healthcare datasets pose privacy and data-breach risks, and implementing advanced AI systems can be expensive and energy-intensive.

As the cannabis industry integrates biotechnology and AI, careful attention is needed to ensure these technologies are deployed responsibly, safely, and equitably.

“Everything starts with education,” Bid emphasizes. By training the next generation of scientists and practitioners, the field of biotechnology and medical cannabis can fully leverage AI and ML—from precision cannabinoid medicine and endocannabidomic profiling to microbiome integration, accelerated drug discovery, and AI-guided patient monitoring. Introduction to these tools will prepare future leaders to innovate, expand applications, and advance AI-driven precision medicine in the cannabis industry.

The post The Power of AI and How it Will Transform Cannabis Medicine appeared first on Cannabis Industry Journal.